Ysios Capital

🎙#Podcast I Segunda entrega del podcast mensual: PÍLDORAS DE BIOTECH! 💊 En colaboración con Enric Miquel de Pharma New Talent y con la participación de Jordi Xiol 🔬 Este mes exploramos la fascinante historia de Alnylam Pharmaceuticals. Con cuatro productos ya en el mercado en EE. UU. y cuatro más en fase 3, descubre la innovadora tecnología de #RNAi que impulsa a esta compañía pionera. 🛋️ Temas destacados en este episodio: [01:14]: Los resultados más esperados del año del sector Biotech [02:32]: 250.000 pacientes en todo el mundo [03:57]: RNA de interferencia, una tecnología revolucionaria [05:29]: Crecer un 60% en bolsa [06:28]: Un poema en LinkedIn [07:49]: De petunias y gusanos a medicina real [11:30]: ARNm y ARNi, puntos en común [13:36]: La fiebre del oro en Farma & Biotech [15:35]: Levantar 4.000 M € en financiación [16:52]: Nuevas dianas terapéuticas para el ARN de interferencia [22:10]: En búsqueda del largo plazo ¡Dale al Play ▶️ y comparte! Disponible en Spotify, Apple e Ivoox. 👉 https://lnkd.in/ebN-s8fW #BiotechInsights #YsiosPodcast #BiotechPillsWithJordi #InnovaciónBiotecnológica #RNAi #AlnylamPharmaceuticals

#PortfolioNews I Our portfolio company Cytoki Pharma has announced positive data from a Phase 1 study evaluating the #safety, #tolerability, and #pharmacokinetics of CK-0045, its lead lipidated IL-22 candidate, in healthy participants and otherwise healthy participants with #obesity. 🎯 Initiation of the Phase 2 is anticipated in the second half of 2024. ✅ CK-0045 induced exposure-dependent reductions in body weight and improvement of key metabolic parameters in participants with #obesity. ✅ Data support advancement of CK-0045 into Phase 2 proof-of-concept studies in individuals with type 2 #diabetes and/or obesity. 👉 Full release - https://bit.ly/46tnWTh 📌 Learn more about the company - https://lnkd.in/dtJhHfSe #Biotech #PharmaNews #ClinicalTrials #DrugDevelopment #WeightLoss #MetabolicHealth #HealthcareInnovation #LifeSciences #vc

#ysiosteam I 🚀 Exciting news! We're thrilled to announce that Thomas Harth has been promoted to #Partner at Ysios Capital! 👏   Since joining us as Principal in March 2022, Thomas has made outstanding contributions to the identification and evaluation of investment opportunities. His journey from Principal to Partner showcases his active involvement in deal sourcing and negotiation, significantly contributing to our growth and success.   In his new role, Thomas will continue to drive investments and help manage our growing portfolio. He has been key in the investments of Tagworks Pharmaceuticals and Memo Therapeutics AG where he serves on the board as well as supported other portfolio companies including Mineralys Therapeutics, Inc. (IPOed on Nasdaq).   Join us in congratulating Thomas on this well-deserved promotion! 🙋♂️ Check Thomas’ profile https://lnkd.in/dPKYPr_6 #Promotion #Leadership #Biotech #Investment #TeamGrowth #Success #vc #Spain #career

💥 What a great evening yesterday !! We at Ysios Capital want to extend a huge thank you to Catalonia.Health (CataloniaBio & HealthTech) for making this record event possible and to the 600 attendees who made it unforgettable. #BBQ2024👏 We are proud to have supported this initiative as sponsors for another year. It was an excellent opportunity for networking, and we were thrilled to share the evening with our industry colleagues. Thank you to everyone who contributed to making this event a remarkable success! Here's to many more years of collaboration ! 🚀 #Cataloniahealth #Networking #biotech #vc #catalonia #WeAreCataloniaBioHT #YsiosCapital

🎙#Podcast I Descubre el nuevo podcast mensual: PÍLDORAS DE BIOTECH! 💊 En colaboración con Enric Miquel de Pharma New Talent y con la participación de Jordi Xiol Cada mes, en episodios de no más de 20 minutos, nuestro #partner Jordi Xiol te traerá lo más Hot🔥en #Pharma & #Biotech 🧪🔬 Diseñado para todos: expertos, no expertos y curiosos. No te lo pierdas! En el primer episodio, exploramos las novedades más importantes de la American Society of Clinical Oncology (ASCO) de Chicago. ¡Dale al Play ▶️ y comparte! Disponible en Spotify, Apple e Ivoox. 👉 https://lnkd.in/dgXdDVqB #BiotechInsights #YsiosPodcast #BiotechPillsWithJordi #oncology #ASCO

#portfolionews I 👏 We are thrilled to congratulate Gloria Gonzalez-Aseguinolaza, Co-Founder and Chief Scientific Officer of Vivet Therapeutics on receiving the prestigious Rosalind Franklin Society Special Award in Science. 🏆 This #award holds special significance as it celebrates the exceptional contributions of #women or under-represented #minorities in #science. 🔷 As investors in Vivet, Ysios Capital is proud to support Gloria and her groundbreaking work on #AAVs. Her #leadership and dedication have been instrumental in creating Vivet’s research platform and advancing development of Vivet’s lead gene therapy for #Wilson’s #Disease 🎯 Our commitment to supporting #WomenInScience is exemplified by leaders like Gloria, whose contribution is making a substantial impact in the field of #GeneTherapy. Learn more about Gloria’s achievements and her vital role at Vivet through the link 👉 https://lnkd.in/dU9wSq6i #Biotech #WilsonDisease #Innovation #Leadership #Healthcare #LifeSciences #RosalindFranklin #Award #YsiosPortfolio

📰 Don't miss out on this exciting read! "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation," by Andrea Chicca, CEO of Synendos Therapeutics AG Therapeutics and Jürg Gertsch. Discover the fascinating journey of Synendos Therapeutics AG , born from a groundbreaking academic project on selective endocannabinoid reuptake inhibitors. A perfect example of how cutting-edge research in academia can lead to innovative drug discoveries. If you're passionate about the intersection of basic research and pharmaceutical innovation, this is a must-read! 📑 Check it out here👉 https://bit.ly/4cR5S7B cc/ Chemistry Europe #Biotech #Innovation #Research #CNSDrugDiscovery #CNS #YsiosPortfolio

📢 #Lastcall I Hurry up!! You're still on time to apply. ❗❗ 🫵 If you hold a #PhD in #LifeSciences, this is your last chance to join our 6-month #ysiosfellowship program and elevate your #career! 🎯 Application Deadline: June 25, 2024 ✍️ Apply Now: https://bit.ly/3LZW5lf #LifeSciences #Biotech #VentureCapital #CareerGrowth #TalentDevelopment #Spain #YsiosTeam #YsiosFellowship #vc

#event I It is a pleasure to sponsor the CataloniaBio & HealthTech BBQ again! 🔝 📌 Join us on July 18 for #BBQ2024! 🤝 Connect with members, partners, and new friends in the #Catalan #health #ecosystem. 🍻 🎟 Tickets are flying fast, so grab yours now! https://lnkd.in/gqn3_Shq Thanks to CataloniaBio & HealthTech for organizing and to Specipig and chef Luis Ruiz-Avila for making it special. See you there! 💥 #CataloniaBIO #Networking #biotech #vc #catalonia #WeAreCataloniaBioHT

#portfolionews I Our portfolio company Xeltis has received Investigational Device Exemption (IDE) approval from FDA - La Administración de Alimentos y Medicamentos for initiation of US pivotal #trial for aXessTM, its restorative vascular access conduit. 👏 👉 Full details here https://bit.ly/4c3uSsf 🎯 aXess is a restorative conduit that enables the creation of a new, permanent, living vessel for #hemodialysis vascular access, combining the #safety and patency of an arteriovenous fistula (AVF), with the speed to treatment of an arteriovenous graft (AVG). The aXess vascular access conduit offers an improved dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by many renal disease patients. 🔬 The #US-based pivotal trial follows strong 12-month data from the first-in-human trial in Europe in comparison to hemodialysis vascular access solutions. aXess is also undergoing an EU pivotal trial, recruiting up to 110 patients in nine #EU countries. #FDA #VascularAccess #IDE #hemodialysis #renal #vc #innovation #MedicalInnovation #Healthcare #RenalCare #FDAApproval #ClinicalTrials